Background
Methods
Patients
Patients with ALL | Patients with OSC | Total | |
---|---|---|---|
Number of patients | 622 | 39 | 661 |
Gender n (%) | |||
Male | 372 (60) | 27 (69) | 399 (60) |
Female | 250 (40) | 12 (31) | 262 (40) |
Age at diagnosis (%) | |||
< 1 yr. n | 7 (1) | 0 | 7 (1) |
1–10 yr. n | 505 (81) | 9 (23) | 515 (78) |
> 10 yr. n | 109 (18) | 30 (77) | 138 (21) |
Mean ± SD yr | 6.39 (±4.3) | 13.1 (±3.5) | 6.6 (±4.3) |
Median (range) yr | 5.2 (0–18) | 13.2 (5–18) | 5.3 (0–18) |
Risk group n (%) | |||
SR | 165 (27) | 3 (7) | 168 (25) |
IR | 355 (57) | 24 (62) | 379 (58) |
HR | 100 (16) | 12 (31) | 112 (17) |
Chemotherapy protocol n (%) | |||
Protocols before 20001 | 325 (52) | − | 325 (52) |
Protocols after 20002 | 297 (48) | − | 297 (48) |
OSC protocols | − | 39 | 39 |
Anthracycline dose3 (range, mg/m2) | 60–840 | 180–360 | 60–840 |
Anthracycline dose n (%) | |||
≤ 240 mg/m2 | 457 (74) | 6 (15) | 463 (70) |
> 240 mg/m2 | 163 (26) | 33 (85) | 196 (30) |
Patients with pathological FS4 n | 18 | 2 | 20 |
Follow-up category | Patients with ALL | Patients with OSC | Total population | ||
---|---|---|---|---|---|
N (mean FS ± SD) | N (mean FS ± SD) | N (mean FS ± SD) | Decreased not decreased FS, N1 | OR (95% CI) 2 | |
At the diagnosis | 358 | 29 | 387 | ||
41.5 ± 6.1 | 39.6 ± 4.4 | 41.4 ± 6.0 | |||
< 1 yr. from diagnosis1 | 275 | 5 | 280 | 104 | 83 | 1.0 |
40.4 ± 6.1 | 40.2 ± 5.3 | 40.4 ± 6.1 | |||
1–2 yr. from diagnosis | 46 | 3 | 49 | 19 | 10 | 1.5 (0.6–3.4) |
41.4 ± 6.0 | 39.9 ± 2.3 | 41.3 ± 5.9 | |||
End of the treatment | 287 | 28 | 315 | 105 | 98 | 0.9 (0.6–1.3) |
40.0 ± 5.6 | 38.4 ± 6.3 | 39.9 ± 5.7 | |||
2–5 yr. from diagnosis | 229 | 35 | 264 | 77 | 73 | 0.8 (0.5–1.3) |
40.4 ± 5.7 | 38.1 ± 5.2 | 40.1 ± 5.7 | |||
5–10 yr. from diagnosis | 265 | 36 | 301 | 70 | 76 | 0.7 (0.5–1.1) |
40.1 ± 5.5 | 40.3 ± 5.6 | 40.1 ± 5.5 | |||
10–15 yr. from diagnosis | 133 | 19 | 152 | 24 | 36 | 0.5 (0.3–1.0) |
40.4 ± 5.4 | 39.9 ± 5.2 | 40.3 ± 5.3 | |||
> 15 yr. from diagnosis | 24 | 8 | 32 | 5 | 3 | 1.3 (0.3–5.7) |
37.6 ± 7.5 | 40.7 ± 6.1 | 38.4 ± 7.2 |
Laboratory methods
Statistical analysis
Results
Case-control analysis
Follow-up analysis
Gene | SNP | Genotype group 1 / group 2 | Mean FS % ± SE genotype group 1 (N) | Mean FS % ± SE genotype group 2 (N) | P value | Follow-up category |
---|---|---|---|---|---|---|
ABCB1
| rs9282564 | AA / AG + GG | 41.5 ± 0.7 (100) | 37.9 ± 1.1 (29) | 2 .50E-03 | 10–15 years after Dx |
ABCC1
| rs35626 | GG / GT + TT | 41.0 ± 0.6 (92) | 39.0 ± 0.6 (127) | 7 .90E-03 | 2–5 years after Dx |
ABCC2
| rs3740066 | GG / GA / AA | 39.5 ± 0.5 (112) | 40.8 ± 0.5 (112) / 42.9 ± 0.9 (33) | 4 .50E-03 | 5–10 years after Dx |
NQO1
| rs1043470 | CC / CT + TT | 40.9 ± 0.5 (198) | 38.1 ± 0.9 (53) | 2 .60E-03 | acute phase |
SLC22A6
| rs6591722 | TT + TA / AA | 40.7 ± 0.4 (227) | 37.8 ± 1.0 (28) | 5 .90E-03 | 5–10 years after Dx |
SLC28A3
| rs7853758 | GG / GA + AA | 41.3 ± 0.7 (96) | 38.4 ± 1.1 (36) | 4 .80E-03 | 10–15 years after Dx |
SLC28A3
| rs885004 | GG / GA + AA | 41.3 ± 0.7 (95) | 38.0 ± 1.1 (33) | 2 .50E-03 | 10–15 years after Dx |
Analysis of fractional shortening alteration
Gene | SNP | Genotype group 1 / group 2 | Patients with decreased FS in genotype groups N (%) | Patients with increased FS in genotype groups N (%) | P value | OR (CI 95%) |
---|---|---|---|---|---|---|
Alteration of FS: diagnosis vs. end of therapy | ||||||
CYP3A4 | rs3735451 | AA / AG + GG | 74 (82) / 16 (18) | 52 (63) / 31 (37) | 5.70E-03 | 0.36 (0.18–0.74) |
CYP3A5 | rs776746 | GG / GA + AA | 81 (91) / 8 (9) | 60 (73) / 22 (27) | 3.80E-03 | 0.26 (0.11–0.65) |
Alteration of FS: diagnosis vs. last echocardiography | ||||||
NQO1 | rs1043470 | CC / CT + TT | 111 (85) / 41 (15) | 112 (73) / 20 (27) | 8.90E-03 | 0.44 (0.24–0.81) |